-
Product Name
Anti-VEGFR3/FLT-4 antibody
- Documents
-
Description
Rabbit polyclonal to VEGFR3/FLT-4
-
Tested applications
ELISA, WB
-
Species reactivity
Human VEGFR3 / FLT4
-
Alternative names
AI323512 antibody; Chy antibody; Flt4 antibody; FLT4 antibody; Flt-4 antibody; FLT41 antibody; LMPH1A antibody; PCL antibody; RP23-58E13.1 antibody; VEGFR3 antibody; VEGFR3 antibody; VEGFR-3 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with purified, recombinant Human VEGFR3 extracellular domain (rhVEGFR3; Met 1-Ile 776; NP_002011.2). VEGFR3 specific IgG was purified by human VEGFR3 affinity chromatography.
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
WB: 10-20 μg/ml
ELISA: 0.5-1.0 μg/mL
This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect VEGFR3. The detection limit for Human VEGFR3 is 0.00245 ng/well.
-
Validations
VEGFR3 / FLT-4 Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot
-
Background
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.
-
References
- Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52.
- Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36.
- Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5.
- Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"